AI assistant
Ipsen — AGM Information 2014
May 13, 2014
1449_agm-r_2014-05-13_13bf0473-3338-4a74-908d-7c32c98b5f7e.pdf
AGM Information
Open in viewerOpens in your device viewer
Ordinary Shareholders' Meeting of 4 June 2014 Availability of documentation for the Shareholders' Meeting
Paris (France), 13 May 2014 – The Shareholders of the Company are invited to participate in the Ordinary Shareholders' Meeting of Ipsen SA to be held on Wednesday 4 June 2014 at 3 pm (Paris time) at La Maison des Arts et Métiers (salon La Rochefoucauld), 9 bis avenue d'Iéna, 75116 Paris, France.
The preliminary notice of meeting containing the agenda and the proposed resolutions has been published in the Bulletin des Annonces Légales Obligatoires (BALO) dated 11 April 2014 and is available on Ipsen's website at the following address: www.ipsen.com.
Documents and information relating to this Meeting will be made available to shareholders under the conditions provided for by legal and regulatory provisions in force.
In accordance with applicable regulatory provisions:
- Registered shareholders can, until the fifth day (inclusive) before the Meeting, request from the Company supply of the said documents, including at their request, by way of an electronic mail. For holders of bearer shares, the exercise of this right is subject to the presentation of a certificate of attendance in the bearer share accounts kept by the empowered intermediary;
- All shareholders can consult these documents at the Company's headquarters.
About Ipsen
Ipsen is a global specialty-driven pharmaceutical company with total sales exceeding €1.2 billion in 2013. Ipsen's ambition is to become a leader in specialty healthcare solutions for targeted debilitating diseases. Its development strategy is supported by 3 franchises: neurology, endocrinology and uro-oncology. Moreover, the Group has an active policy of partnerships. Ipsen's R&D is focused on its innovative and differentiated technological platforms, peptides and toxins. In 2013, R&D expenditure totaled close to €260 million, representing more than 21% of Group sales. Moreover, Ipsen also has a significant presence in primary care. The Group has close to 4,600 employees worldwide. Ipsen's shares are traded on segment A of Euronext Paris (stock code: IPN, ISIN code: FR0010259150) and eligible to the "Service de Règlement Différé" ("SRD"). The Group is part of the SBF 120 index. Ipsen has implemented a Sponsored Level I American Depositary Receipt (ADR) program, which trade on the over-the-counter market in the United States under the symbol IPSEY. For more information on Ipsen, visit www.ipsen.com.
For further information:
Media Didier Véron Brigitte Le Guennec Senior Vice President, Public Affairs and Communication Tel.: +33 (0)1 58 33 51 16 Fax: +33 (0)1 58 33 50 58 Email: [email protected]
Financial Community Pierre Kemula Stéphane Durant des Aulnois Vice President, Corporate Finance, Treasury and Financial Markets Tel.: +33 (0)1 58 33 60 08 Fax: +33 (0)1 58 33 50 63 E-mail: [email protected]
Media and Public Relations Officer Tel. : +33 (0)1 58 33 51 17 Fax : 01 58 33 50 58 Email : [email protected]
Investor Relations Director Tel.: +33 (0)1 58 33 60 09 Fax: +33 (0)1 58 33 50 63 Email: [email protected]
REGULATED INFORMATION
Thomas Peny-Coblentz, CFA
Deputy Director Investor Relations Tel.: +33 (0)1 58 33 56 36 Fax: +33 (0)1 58 33 50 63 E-mail: [email protected]